30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual base-case ICER.

The PBAC's ICER threshold is expressed in the Public Summary Documents as a band; $45,000 - $75,000/QALY gained. An examination of the Public Summary Documents for the submissions recommended at the July 2018 PBAC meeting on a cost-effectiveness basis reveals the following acceptable base-case ICERs ($/QALY gained):

• Avelumab - $45,000 - $75,000
  
• Crizotinib - $45,000 - $75,000
  
• Everolimus - $75,000 - $105,000
  
• Guanfacine hydrochloride - $15,000 - $45,000
  
• Midostaurin - $45,000 - $75,000
  
• Pembolizumab (Bladder cancer) - <$60,000
  
• Pembrolizumab (NSCLC) - $45,000 - $75,000
• Trifluridine with tipiracil hydrochloride - $45,000 - $75,000
  

As usual this list is incomplete; the Public Summary Documents for some other medicines/combination products recommended on a cost-effectiveness basis do not cite the final base-case ICER. The inconsistent publication of accepted base-case ICERs is typical.